MeOPP is anecdotally said to induce significantly less anxiety than similar piperazines, and is usually taken at doses between 120–200 mg. It does not produce prominent stimulant effects, but is instead said to be relaxing, however it is often mixed with stimulant piperazine derivatives such as benzylpiperazine (BZP) for a combined effect.
IUPAC name: 1-(4-methoxyphenyl)piperazine
Other names: para-Methoxyphenylpiperazine, pMPP, 4-MPP; Paraperazine
CAS number: 38212-30-5
Purity: 99% min
Appearance: white powder
MeOPP has been found in vitro to inhibit the reuptake and induce the release of the monoamine neurotransmitters. This is a mechanism of action shared with drugs of abuse such as amphetamines, and MeOPP produces somewhat similar effects although it is much less potent and is thought to have relatively insignificant abuse potential